Racura Oncology says both Phase 1 RC220 programs have cleared their opening dose cohorts without dose-limiting toxicities, while its Korean expansion broadens the CPACS trial. The company ended September with $30.7 million in cash, which management says funds committed activities into mid-2028.
- HARNESS-1 cleared its first two-patient 50 mg/m² cohort
- CPACS expanded to South Korea after its opening dose cohort
- $30.735 million cash balance at 30 September
- Management estimates funding through mid-2028
- Appendix 4C cash movement figures appear internally inconsistent
RC220 clears opening safety cohorts
Racura Oncology Ltd (ASX:RAC) has moved both of its early-stage RC220 programs past their first safety checkpoints, giving the clinical-stage biotech more room to advance its lead drug while it recruits across a wider international network.
In the HARNESS-1 trial, which is testing RC220 with osimertinib in patients with EGFR-mutated non-small cell lung cancer, two patients treated at 50 mg/m² had no dose-limiting toxicities or treatment-related safety concerns identified. The Safety Review Committee has since cleared escalation to the next planned dose level of 100 mg/m². These are preliminary safety observations, not evidence of efficacy.
The progress builds on the Bellberry trial approval, which enabled additional Australian sites including Chris O’Brien Lifehouse and Austin Health to move through governance and start-up activities. Racura says the extra sites are intended to improve patient access and support recruitment, although the report does not provide an enrolment figure or a timetable for completing the trial.
CPACS gains a South Korean foothold
Racura’s second Phase 1 program, CPACS, has also passed its first dose cohort without dose-limiting toxicities. The trial is evaluating RC220 with doxorubicin in patients with advanced solid tumours, with the company pursuing a combination intended to provide both anticancer and cardioprotective benefits.
South Korea is now part of that recruitment effort. The first Korean site was activated during September, with further sites expected to open shortly afterwards. The expansion follows the South Korea CPACS expansion, which had identified three leading Korean oncology centres for the program. Racura says the broader site network should accelerate recruitment and trial progress, but the quarterly report does not quantify the expected contribution from Korea.
Cash runway supports continued development
Racura held $30.735 million in cash and cash equivalents at 30 September. Operating activities used $3.542 million during the quarter, including $2.739 million for research and development, while investing activities absorbed a further $13,000. Management says the cash balance is sufficient to fund committed activities into mid-2028; that remains a company estimate and will depend on spending and development progress.
The Appendix 4C also contains a presentation issue worth noting. Its line for the net increase in cash shows $34.290 million, while the reported closing balance fell from $34.290 million in the previous quarter to $30.735 million. The stated operating and investing outflows likewise imply a net decrease of about $3.555 million, rather than an increase. The closing cash figure and the cash reconciliation are clear, but the movement line does not reconcile on its face.
Next clinical readouts carry the burden
Racura’s quarterly update is strongest on trial execution: new sites, a first dose escalation in HARNESS-1 and a wider CPACS recruitment footprint. It also reports new preclinical data supporting RC220’s proposed G4-binding mechanism and inhibition of MYC gene transcription, alongside presentations at international cardio-oncology and cancer conferences.
The more consequential test now is whether the programs can turn clean early safety findings into meaningful recruitment, tolerability at higher doses and eventually efficacy data. Until those results emerge, the cash runway reduces near-term funding pressure but does not resolve the clinical risk attached to RC220.
Bottom Line?
Racura has bought time and expanded access to patients, but the investment case still turns on what happens after dose escalation and whether early safety can translate into clinical benefit.
Questions in the middle?
- How quickly will the additional Australian and South Korean sites translate into measurable patient recruitment?
- Will RC220 continue to show an acceptable safety profile as HARNESS-1 advances to 100 mg/m² and beyond?
- How will Racura reconcile the Appendix 4C cash movement figure with its reported balances and cash flows?